Treatment margins predict biochemical outcomes after prostate brachytherapy

Cancer Journal

Volumn 10, Issue 3, 2004, Pages 175-180

  Choi, Seungtaek ^a,b   Wallner, Kent E ^a,b,c,d,f   Merrick, Gregory S ^a,e   Cavanagh, William ^a,c   Butler, Wayne M ^a,e  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Puget Sound Health Care System   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e WHEELING HOSPITAL   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Brachytherapy; Dosimetry; Prostatic carcinoma; Treatment margins

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ARTICLE; BLADDER; BRACHYTHERAPY; CANCER STAGING; CHEMICAL ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RADIATION DOSE; TREATMENT INDICATION; UNIVARIATE ANALYSIS; CLASSIFICATION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; METHODOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOMETRY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 4644280613     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200405000-00007     Document Type: Article

References (21)

1. Potters L, Cao Y, Calugaru E et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Rad Oncol Biol Phys 2001;50:605-614.
2. Stock RG, Stone NN, Lo YC et al. Postimplant dosimetry for 125-I prostate implants: Definitions and factors affecting outcome. Int J Rad Oncol Biol Phys 2000;48:899-906.
3. Merrick GS, Butler WM, Wallner KE et al. Extracapsular dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 2003;26:178-189.
4. Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. Int J Rad Oncol Biol Phys 2001;51:1196-1199.
5. Han B, Wallner K, Aggarwal S et al. Treatment margins for prostate brachytherapy. Semin Urol Oncol 2000;18:137-141.
6. Davis BJ, Pisansky TM, Wilson TM et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999;85:2630-2637.
7. Sohayda C, Kupelian PA, Levin JS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urol 2000;55:382-386.
8. Wallner K, Blasko J, Dattoli M. Supplemental beam radiation. In: Dattoli M, ed. Prostate brachytherapy made complicated (second edition), ed. 2 Seattle: SmartMedicine Press, 2001;11.1-11.23.
9. 103Pd for low risk prostate cancer: Morbidity outcomes from a prospective randomized multicemer trial. Cancer J 2002;8:67-73.
10. 103Pd for low risk prostate cancer: Preliminary biochemical outcomes from a prospective randomized multicenter trial. Int J Rad Oncol Biol Phys 2003;57:1297-1303.
11. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Techniques in Urology 2000;6:78-84.
12. Schwartz D, Billingsley K, Wallner K. Follow-up care for cancer: Making the benefits equal the cost. Oncology 2000;14:1493-1505.
13. Tralins K, Wallner K. Follow-up costs after external beam irradiation for low risk prostate cancer. Int J Rad Oncol Biol Phys 1999;44:323-326.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Merrick GS, Butler WM, Dorsey AT, Lief JH. Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Rad Oncol Biol Phys 1999;44:717-724.
16. D'Amico AV, Davis A, Vargas SO et al. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? Int J Rad Oncol Biol Phys 1999;43:587-590.
17. Han B, Wallner K, Merrick G et al. The effect of inter-observer differences in post-implant prostate CT image interpretation on dosimetric parameters. Med Phys 2003;30:1096-1104.
18. Dicker AP, Lin C-C, Leeper DB, Waterman FM. Isotope selection for permanent prostate implants? An evaluation of 103-Pd versus 125-1 based on radiobiological effectiveness and dosimetry. Seminars in Urol Oncol 2000;18:152-159.
19. Wieder J, Soloway M. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315.
20. Bice WS, Prestidge BR, Sarosody MF. Sector analysis of prostate implants. Med Phys 2001;28:2561-2567.
21. Sidhu S, Morris WJ, Spadinger I et al. Prostate brachytherapy postimplant dosimetry: A comparison of prostate quadrants. Int J Rad Oncol Biol Phys 2002;52:544-552.